Pharmaceutical composition for use in the treatment of pancreatic cancer
OwnerJoachim AERTS, Floris DAMMEIJERinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for the treatment of pancreatic cancer comprising administering to a patient in need thereof a CD40 agonist in combination with dendritic cells loaded with a lysate of mesothelioma cells. A further aspect of the present invention relates to dendritic cells loaded with a lysate of mesothelioma cells for use in the treatment of pancreatic cancer. A last aspect of the present invention relates to a pharmaceutical composition comprising such loaded dendritic cells.
Claims20
A method for the treatment of pancreatic cancer, comprising administering to a patient in need thereof a CD40 agonist in combination with dendritic cells loaded with a lysate, wherein the lysate is obtainable by a method comprising:
- (i) providing human mesothelioma tumour cells from at least two different mesothelioma tumour cell lines;
- (ii) inducing necrosis in the tumour cells;
- and
- (iii) lysing the necrotic tumour cells, such that a lysate is obtained.
A pharmaceutical composition, obtainable by a method comprising:
- (i) preparing a lysate of allogeneic mesothelioma tumour cells from at least two different cell lines;
- and
- (ii) loading dendritic cells with the lysate of tumour cells and, optionally, adding a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.